International Journal of Hypertension [95] J. C. T. Pepperell, S. Ramdassingh-Dow, N. Crosthwaite et al., “Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial,” Lancet, vol. 359, no. 9302, pp. 204–210, 2002. [96] M. Barnes, D. Houston, C. J. Worsnop et al., “A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 6, pp. 773–780, 2002. [97] H. F. Becker, A. Jerrentrup, T. Ploch et al., “Eﬀect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea,” Circulation, vol. 107, no. 1, pp. 68–73, 2003. [98] D. Norman, J. S. Loredo, R. A. Nelesen et al., “Eﬀects of con- tinuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure,” Hypertension, vol. 47, no. 5, pp. 840–845, 2006. [99] G. V. Robinson, D. M. Smith, B. A. Langford, R. J. O. Davies, and J. R. Stradling, “Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients,” European Respiratory Journal, vol. 27, no. 6, pp. 1229–1235, 2006. [100] F. Campos-Rodriguez, A. Grilo-Reina, J. Perez-Ronchel et al., “Eﬀect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo- controlled trial,” Chest, vol. 129, no. 6, pp. 1459–1467, 2006. [101] D. S. Hui, K. W. To, F. W. Ko et al., “Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness,” Thorax, vol. 61, no. 12, pp. 1083–1090, 2006. [102] S. R. Coughlin, L. Mawdsley, J. A. Mugarza, J. P. H. Wilding, and P. M. A. Calverley, “Cardiovascular and metabolic eﬀects of CPAP in obese males with OSA,” European Respiratory Journal, vol. 29, no. 4, pp. 720–727, 2007. [103] M. Kohler, J. C. T. Pepperell, B. Casadei et al., “CPAP and measures of cardiovascular risk in males with OSAS,” Euro- pean Respiratory Journal, vol. 32, no. 6, pp. 1488–1496, 2008. [104] F. Campos-Rodriguez, J. Perez-Ronchel, A. Grilo-Reina, J. Lima-Alvarez, M. A. Benitez, and C. Almeida-Gonzalez, “Long-term eﬀect of continuous positive airway pressure on BP in patients with hypertension and sleep apnea,” Chest, vol. 132, no. 6, pp. 1847–1852, 2007. [105] F. Barbe, J. Duran-Cantolla, F. Capote et al., “Long-term eﬀect of continuous positive airway pressure in hypertensive patients with sleep apnea,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 718–726, 2010. [106] N. Jaimchariyatam, C. L. Rodriguez, and K. Budur, “Does CPAP treatment in mild obstructive sleep apnea aﬀect blood pressure?” Sleep Medicine, vol. 11, no. 9, pp. 837–842, 2010. [107] L. A. Bazzano, Z. Khan, K. Reynolds, and J. He, “Eﬀect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea,” Hypertension, vol. 50, no. 2, pp. 417–423, 2007. [108] P. Haentjens, A. van Meerhaeghe, A. Moscariello et al., “The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials,” Archives of Internal Medicine, vol. 167, no. 8, pp. 757–765, 2007. 13 [109] M. Alajmi, A. T. Mulgrew, J. Fox et al., “Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta- analysis of randomized controlled trials,” Lung, vol. 185, no. 2, pp. 67–72, 2007. [110] J.-L. Pe´pin, R. Tamisier, G. Barone-Rochette, S. H. Launois, P. Le´vy, and J.-P. Baguet, “Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 7, pp. 954–960, 2010. [111] G. V. Robinson, J. R. Stradling, R. J. O. Davies et al., “Sleep · 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension,” Thorax, vol. 59, no. 12, pp. 1089–1094, 2004. [112] A. G. Logan, R. Tkacova, S. M. Perlikowski et al., “Refractory hypertension and sleep apnoea: eﬀect of CPAP on blood pressure and baroreﬂex,” European Respiratory Journal, vol. 21, no. 2, pp. 241–247, 2003. [113] M. A. Martı´nez-Garcı´a, R. G o´mez-Aldaravı´, J. J. Soler- Catalun˜a, T. G. Martı´nez, B. Berna´cer-Alpera, and P. Rom a´n-S a´nchez, “Positive eﬀect of CPAP treatment on the control of diﬃcult-to-treat hypertension,” European Respiratory Journal, vol. 29, no. 5, pp. 951–957, 2007. [114] T. A. Dernaika, G. T. Kinasewitz, and M. M. Tawk, “Eﬀects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea,” Journal of Clinical Sleep Medicine, vol. 5, no. 2, pp. 103–107, 2009. [115] L. Lozano, J. L. Tovar, G. Sampol et al., “Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial,” Journal of Hypertension, vol. 28, pp. 2161–2168, 2010. [116] C. J. Stepnowsky Jr. and P. J. Moore, “Nasal CPAP treatment for obstructive sleep apnea: developing a new perspective on dosing strategies and compliance,” Journal of Psychosomatic Research, vol. 54, no. 6, pp. 599–605, 2003. [117] H. M. Engleman and M. R. Wild, “Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS),” Sleep Medicine Reviews, vol. 7, no. 1, pp. 81–99, 2003. [118] T. E. Weaver and R. R. Grunstein, “Adherence to continuous positive airway pressure therapy: the challenge to eﬀective treatment,” Proceedings of the American Thoracic Society, vol. 5, no. 2, pp. 173–178, 2008. [119] H. Kraiczi, J. Hedner, Y. Peker, and L. Grote, “Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 5, pp. 1423–1428, 2000. [120] K. Gaddam, E. Pimenta, S. J. Thomas et al., “Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report,” Journal of Human Hypertension, vol. 24, no. 8, pp. 532–537, 2010. [121] J. W. Conn, “Presidential address. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome,” Journal of Laboratory and Clinical Medicine, vol. 45, no. 1, pp. 3–17, 1955. [122] N. M. Kaplan, “Is there an unrecognized epidemic of primary aldosteronism? Con.,” Hypertension, vol. 50, no. 3, pp. 454–458, 2007. [123] D. A. Calhoun and N. M. Kaplan, “Is there an unrecognized epidemic of primary aldosteronism? (Pro),” Hypertension, vol. 50, no. 3, pp. 447–458, 2007.